A 23-year-old Japanese woman was admitted to A hospital due to pneumonia. IgM for Mycoplasma pneumoniae was positive, and the patient was treated with imipenem/cilastatin, clindamycin, pazufloxacin and minocycline. However, both the chest radiological findings and the symptoms became exacerbated, and she was therefore transferred to our hospital. The bronchoalveolar lavage fluid was obtained, and a 16S rRNA gene sequencing analysis revealed a monobacterial infection of Mycoplasma pneumoniae. Therefore, corticosteroid treatment in addition to minocycline was administered, and the patients symptoms, laboratory data and chest radiographs improved. Corticosteroid therapy may therefore be considered for patients with refractory M. pneumoniae pneumonia.
Introduction
Mycoplasma pneumoniae pneumonia is one of the common types of atypical pneumonia and is typically successfully treated with macrolides, respiratory quinolone, and tetracycline; however, it may occasionally worsen even under proper antimicrobial treatment. M. pneumoniae pneumonia is essentially a reaction of the host defense as well as infectious aspects, however, excessive reactions of the host immunity may exacerbate the pneumonia, and the precise mechanism of exacerbation of pneumonia in severe M. pneumoniae pneumonia has not yet been fully elucidated. We herein present a patient with M. pneumoniae pneumonia who was confirmed to have a monobacterial infection of M. pneumoniae by a 16S ribosomal RNA gene sequencing analysis and bacterial cell count using ethidium bromide staining of the bronchoalveolar lavage fluid. Although the initial treatment with appropriate antimicrobials for M. pneumoniae pneumonia was unsuccessful, the patient was successfully treated with additional systemic corticosteroid treatment. 
ance in the right upper lobe with right pleural effusion. Upon admission to A hospital, her transcutaneous saturation of oxygen was 97% (room air) and her body temperature was 40.3 . The laboratory findings demonstrated a white blood cell count within the normal range (5,800/μL), an increased serum C-reactive protein (CRP) level (23.4 mg/dL) and a positive result for the Mycoplasma pneumoniae IgM antibody test. According to these findings, the patient was diagnosed with M. pneumoniae pneumonia. Treatment with pazufloxacin (PZFX, 1 g/day) was initiated on the day of admission, however, her chest X-ray and fever pattern worsened. PZFX was changed to imipenem/cilastatin and clindamycin (IPM/CS, 1 g/day and CLDM, 1 g/day) on the 4th day of admission, followed by an additional treatment of minocycline (MINO, 200 mg/day) on the 6th day of admission. However, the infiltrations in the right lung, hypoxemia, an increased fever and dyspnea all continued to worsen.
The patient was then transferred from A hospital to our hospital for further treatment. No abnormal findings were audible in the bilateral lung fields on auscultation. The laboratory findings on this admission (Table) demonstrated a normal white blood cell count (7,200/μL), increased serum levels of lactate dehydrogenase (LDH) (657 IU/mL) and CRP (20.1 mg/dL), hypoalbuminemia (2.1 g/dL) and hypoxemia (partial pressure of arterial oxygen (PaO2) 75 mmHg on nasal oxygen support of 2 L/min). The chest Xray ( Fig. 1A) and CT (Fig. 1B, C) on the day of transfer to our hospital revealed consolidations in the right upper and middle lung fields with bilateral pleural effusions and reticulonodular shadows in the left lingular segment. The treatment with MINO (200 mg/day) was continued, and a bronchoalveolar lavage fluid (BALF) specimen was obtained from the right S 3 using fiberoptic bronchoscopy on the same day. The bacterial composition of the BALF specimen was analyzed using a clone library analysis of the 16S rRNA gene and the total bacterial cell counts were determined using epifluorescence microscopy as previously described (1).
Briefly, DNA samples were extracted from the BALF specimen and 580 partial base pairs of the 16S rRNA gene were amplified via polymerase chain reaction (PCR) using specific primer pairs. The PCR products were then cloned with a TOPO TA cloning kit (Invitrogen; Carlsbad, USA), and the clone library was constructed. Ninety-six clones were randomly chosen from the clone library, and the sequences of the 16S rRNA gene were determined. A homology search comparing the sequences with the recorded reference strains was performed using the basic local alignment search tool (BLAST) algorithm. In addition, ethidium bromide staining was used to determine the bacterial cell count in the sample. As a result, 98.6% (68/69 clones) of the bacterial clones in the sample determined using this molecular method were identified to be M. pneumoniae, and the numbers of bacteria using ethidium bromide staining was 4.6×10 6 cells/mL, however, the conventional cultivation methods of the BALF did not identify any pathogens. According to these results, the patient was confirmed to have monobacterial pneumonia caused by M. pneumoniae four days after the day of transfer. She still had a high-grade fever and high serum CRP levels with unchanged chest X-ray findings six days after this admission. Therefore, additional treatment with prednisolone (PSL, 40 mg/day) was started in combination with MINO (200 mg/day). Following this combination therapy, the patient's symptoms, such as the fever and cough, laboratory data (CRP levels) and the chest radiologic findings gradually improved (Fig. 2) . PSL was tapered, MINO and PSL were eventually discontinued 12 days after the transfer day, and the patient was discharged without any complications.
Discussion
In the present patient, additional treatment with corticosteroid dramatically improved the M. pneumoniae pneumonia even under appropriate antimicrobial treatment. In ad- M. pneumoniae infection is common in communityacquired pneumonia among young adults and children (1) . Most patients infected with M. pneumoniae do not develop severe pneumonia. In fact, only 3 to 10% of the infected patients actually develop pneumonia (2) .
M. pneumoniae infection is established by the attachment of the bacteria to the surface membrane of ciliated epithelial cells, and the direct injury of the alveolar epithelial cells and pulmonary interstitium (3) . M. pneumoniae lack a cell wall and are covered by many lipoproteins. The pathogenesis of M. pneumoniae is believed to be immune-mediated induced by these lipoproteins rather than induced directly by the bacteria. The lipoproteins of M. pneumoniae are recognized by toll-like receptors (TLR) (e.g., TLR-2/TLR-6 and TLR-1/ TLR-2) on alveolar macrophages (4), and these macrophages can be activated and in turn secrete proinflammatory cytokines, such as interleukin (IL)-12, and other chemokines.
M. pneumoniae pneumonia may occasionally develop into severe pneumonia, progress to respiratory failure and even occasionally be fatal, despite the administration of appropriate antibiotic treatment, even in healthy subjects. Previous reports demonstrated that only 2% of all patients with M. pneumoniae pneumonia required hospitalization (5), and approximately 0.5-10.9% of the inpatients required mechanical ventilation (6, 7) . The comprehensive mechanism of the severe respiratory distress in patients with M. pneumoniae pneumonia had been unclear thus far, however, several reports have estimated that it may be due to mononuclear cell migration into the airway, which results in pulmonary infiltrates. M. pneumoniae can be phagocytized by the macrophages after opsonization of M. pneumoniae by complement or antibodies. The macrophages are activated to release cytokines and chemokines, and mononuclear cell infiltrations (via T-and B-cells or plasmacytes) to the lung occurs (5, (8) (9) (10) (11) (12) ). The immune response is then amplified by the further release of proinflammatory chemical mediators (9). Tanaka et al. (13) demonstrated that the serum levels of IL-18, which promotes the induction of Th1 cytokines, thus leading to the activation of alveolar macrophages and the cellular immune response, were elevated during the acute phase of M. pneumoniae pneumonia. Moreover, circulating IL-18 values had a positive correlation with the number of affected pulmonary lobes.
The downregulation of the cell-mediated immune response by corticosteroids has been previously reported (14, 15) and therefore the additional corticosteroid treatment during severe M. pneumoniae pneumonia may have a favorable effect by reducing the hyperimmunemediated pulmonary injury. In addition, corticosteroids downregulate the immune responses mediated by Th1 cells, and therefore corticosteroids may reduce the immunemediated pulmonary injury induced by M. pneumoniae. Animal experimental models have shown that corticosteroids downregulate the host immune response. Furthermore, treatment with the combination of clarithromycin and a corticosteroid, compared to clarithromycin alone, resulted in a significant reduction of IL-12, p40 and regulated on activation, normal T cell expressed and secreted (RANTES) (16) . Izumikawa reported that the respiratory functions of a majority of fulminant M. pneumoniae pneumonia patients were successfully improved with corticosteroid treatment within 3-5 days, which was also considered to be due to a suppressive effect of the corticosteroids on hyper-activated cellular immunity (17) . In children, You et al. (18) demonstrated that three-day methylprednisolone pulse therapy improved the clinical symptoms, radiological findings and CRP levels in severe refractory childhood M. pneumoniae pneumonia. In adults, Miyashita et al. (19) demonstrated that in 227 adults with M. pneumoniae pneumonia, 13 patients required intensive care unit admission due to acute respiratory failure. In addition, all the cases received corticosteroids with adequate antibiotics, and their conditions promptly improved.
The molecular method we used (1, 20) can be used to identify pathogens that are generally difficult to cultivate using the ordinary cultivation methods, such as M. pneumoniae, and was identical for evaluating the bacterial flora in the sample. In general, complicated or refractory M. pneumoniae pneumonia tends to be considered to be a mixed infection of M. pneumoniae and other bacteria, therefore broad-spectrum antibiotics in addition to the agents effective for treating M. pneumoniae tend to be administered. In particular, a mixed bacterial infection with M. pneumoniae has been considered in all patients who show severe respiratory failure due to M. pneumoniae pneumonia. However, thus far, no previous reports of M. pneumoniae pneumonia that was successfully treated with corticosteroid and strictly confirmed a monobacterial infection caused by M. pneumoniae have been reported. In the present patient, the molecular method using the BALF specimen revealed that the pneumonia of the present patient was due to a monobacterial infection of M. pneumoniae. In addition to the molecular analysis using the 16S rRNA gene, we used ethidium bromide staining to perform bacterial cell counting in the sample (1) , and the total cell count of the specimen obtained from the BALF sample was 4.6×10 6 cells/mL. This number of bacterial cells was more than the median (2.6×10 6 cells/mL) of bacterial cell numbers in the BALF samples in patients with community-acquired pneumonia before starting antimicrobial treatment (1). Even after receiving antimicrobial treatment with PZFX and MINO for approximately one week, a considerable number of M. pneumoniae was still observed in the BALF, and additive systemic corticosteroid treatment with MINO showed a prompt favorable improvement. According to the results of the BALF sample and the clinical response to additive systemic corticosteroid treatment in this patient, it is speculated that an excessive biological response to a relatively large amount of bacterial cells that might be viable or inviable may exacerbate the disease condition in refractory patients with M. pneumoniae pneumonia, and additive systemic corticosteroid treatment may suppress this excessive biological reaction, thus leading to a favorable clinical outcome. Therefore, additive systemic corticosteroid treatment may occasionally be effective in some patients with severe or refractory M. pneumoniae pneumonia.
In conclusion, we herein presented a case of successful additional corticosteroid treatment of a monobacterial infection of M. pneumoniae pneumonia, which was confirmed by the clone library analysis of the 16S rRNA gene and ethidium bromide staining using the BALF specimen. Additive systemic corticosteroid treatment to proper antimicrobials should occasionally be considered for the treatment of patients with severe or refractory M. pneumoniae pneumonia.
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